0000939767-17-000025.txt : 20170303
0000939767-17-000025.hdr.sgml : 20170303
20170303202012
ACCESSION NUMBER: 0000939767-17-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170303
FILED AS OF DATE: 20170303
DATE AS OF CHANGE: 20170303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0102
BUSINESS ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 210 E. GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Senner Christopher J.
CENTRAL INDEX KEY: 0001648367
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 17666248
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wf-form4_148859039767320.xml
FORM 4
X0306
4
2017-03-03
0
0000939767
EXELIXIS, INC.
EXEL
0001648367
Senner Christopher J.
C/O EXELIXIS, INC.
210 EAST GRAND AVE.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
EVP and CFO
Common Stock
2017-03-03
4
S
0
11000
22.80
D
100398
D
Common Stock
1783
I
By 401(k)
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.80 to $22.81. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 5,422 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan. The total number of shares reported has been reduced by 20,000 shares due to prior inadvertent over-reporting of the total number of shares beneficially owned by the Reporting Person.
Represents 1,783 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 2, 2017.
/s/ Jeffrey J. Hessekiel, Attorney in Fact
2017-03-03